Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NF2
REST API REST API
Homo sapiens
NF2 is differentially expressed in 348 experiments: 184 organism parts: cerebellum, testis, ... (182 more);, 302 disease states: normal, acute promyelocytic leukemia, ... (300 more);, 107 cell types 496 cell lines 58 compound treatments and 79 other conditions.
Synonyms merlin
Orthologs Nf2 (Mus musculus)   nf2a (Danio rerio)   Nf2 (Rattus norvegicus)   NF2 (Bos taurus)   ENSCING00000006067 (Ciona intestinalis)   NF2 (Gallus gallus)   Mer (Drosophila melanogaster)   nf2 (Xenopus laevis)   NF2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term extrinsic to membrane, plasma membrane, mesoderm formation, adherens junction, negative regulation of JAK-STAT cascade, protein binding, cleavage furrow, cytoskeleton, cytoplasm, regulation of cell proliferation, negative regulation of cell proliferation, negative regulation of protein kinase activity, ruffle, cell-cell junction organization, negative regulation of DNA replication, filopodium, actin cytoskeleton organization, early endosome, nucleus, negative regulation of cell migration, lamellipodium, perinuclear region of cytoplasm, binding, cytoskeletal protein binding, negative regulation of MAPKKK cascade, ectoderm development, nucleolus, filopodium membrane, negative regulation of cell-cell adhesion, negative regulation of tyrosine phosphorylation of Stat5 protein, lens fiber cell differentiation, regulation of hippo signaling cascade, positive regulation of stress fiber assembly, negative regulation of tyrosine phosphorylation of Stat3 protein, odontogenesis of dentine-containing tooth, negative regulation of cell-matrix adhesion, Schwann cell proliferation, ruffle membrane
InterPro Term Ez/rad/moesin, ERM_C, FERM_central, Band_41_domain, Tropomyosin, ERM, FERM_domain, Band_41_fam, FERM_N, FERM_PH-like_C
UniProt Accession P35240, Q9NRW8, B7Z4B6
Gene-Disease Assocation SCHWANNOMATOSIS, MENINGIOMA, FAMILIAL, NEUROFIBROMATOSIS, TYPE II; NF2
Search EB-eye ENSG00000186575
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (51 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
MDAMB453
2
E-MTAB-37, E-MTAB-62
BT20
2
E-MTAB-62, E-MTAB-37
primary culture
2
E-GEOD-2450, E-GEOD-1657
T84
2
E-GEOD-1474, E-MTAB-37
BT-474
2
E-GEOD-5823, E-GEOD-3529
490 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (48 experiments)

Factor Value U/D Experiments
mononuclear
2
E-GEOD-26672, E-GEOD-13987
endothelial cell
1
2
E-GEOD-3920, E-GEOD-19240, E-GEOD-3998
CD4+ T cell
1
2
E-MTAB-25, E-MTAB-24, E-GEOD-16190
fibroblast
1
2
E-GEOD-3920, E-GEOD-26672, E-GEOD-3204
endothelial cells and pericytes
1
E-MEXP-1251
SVGR2
1
E-GEOD-7819
101 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, ... (74 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MTAB-62, E-MEXP-2034, E-GEOD-7307, E-GEOD-96
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
gastric carcinoma
3
E-MTAB-37, E-GEOD-15460, E-GEOD-2685
glioblastoma
3
E-MTAB-62, E-GEOD-6014, E-MTAB-37
Ewing sarcoma
2
E-MTAB-37, E-GEOD-1825
malignant melanoma
2
E-MTAB-62, E-GEOD-3189
296 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-GEOD-3720, ... (34 experiments)

Factor Value U/D Experiments
none
5
7
E-GEOD-5824, E-MEXP-1958, E-TABM-782, E-MEXP-1230, E-GEOD-412, ... (12 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
actinomycin D
1
E-GEOD-6400
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
heregulin
1
E-GEOD-6462
52 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
67
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-19348, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, ... (11 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, E-TABM-147, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-GEOD-18005, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-10315, E-TABM-440, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-2487 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-19330, E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, ... (6 experiments)

Tumor size
studied in E-GEOD-4922

Processing time: 0.282 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM